Related Experiment Videos
[Intraperitoneal chemotherapy]
1Dept. of Obstetries and Gynecology Fukuyama National Hospital.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|February 1, 1989
Summary
Intraperitoneal chemotherapy is re-emerging as a promising treatment for refractory intraabdominal cancers. This approach focuses on improving drug delivery and efficacy for complete cure.
Area of Science:
- Oncology
- Pharmacology
- Surgical Oncology
Context:
- The Second International Conference of Intracavitary Chemotherapy highlighted renewed interest in intraperitoneal chemotherapy.
- Intraabdominal cancers present significant treatment challenges, often requiring novel therapeutic strategies.
- Refractory cases necessitate advanced administration routes for improved outcomes.
Purpose:
- To review the fundamental principles and challenges of intraperitoneal chemotherapy.
- To analyze the pharmacokinetic differences between intravenous and intraperitoneal cisplatin (CDDP) administration.
- To discuss ongoing clinical trials and future directions for intraperitoneal chemotherapy.
Summary:
- Explores basic issues in intraperitoneal chemotherapy, including peritoneal circulation, clearance, infusion conditions, and drug penetration depth.
- Compares intravenous (IV) versus intraperitoneal (IP) cisplatin pharmacokinetics, noting differences in ultrafilterable platinum values.
- Introduces current clinical trials such as CDDP-STS combination, CDDP-STS-Angiotensin II, CHPP, and IPCP.
Impact:
- Intraperitoneal chemotherapy offers a potential route for complete cure in refractory intraabdominal cancers.
- Understanding pharmacokinetic variations is crucial for optimizing IP chemotherapy regimens.
- Ongoing research and clinical trials are paving the way for advanced IP chemotherapy applications.